Andrea Cipriani, MD, was the lead author of the study at the University of Oxford in the U.K. He conducted a systematic review and analysis of all published and unpublished randomized clinical trials comparing the effects of 14 antidepressants in young people with major depressive disorder. The study included 34 trials involving 5,260 patients.
Researchers assessed the drugs on efficacy, tolerability, acceptability and associated serious issues like suicidal thoughts and attempts.
Out of 14 antidepressants, only fluoxetine — sold as Prozac and Sarafem — relieved symptoms more effectively than a placebo pill and had benefits that outweighed its risks.
Nortriptyline — sold as Pamelor — was significantly less effective than seven other antidepressants and a placebo pill. Imipramine — known as Tofranil — and duloxetine — sold as Cymbalta, ranked lowest for tolerability. Venlafaxine was also ranked low for tolerability and showed an increased risk of suicidal thoughts or attempts.
While researchers say the study provides the most comprehensive analysis to date of commonly prescribed antidepressant use in children and teens, they caution that further research is necessary to determine the drugs’ true effectiveness and potential for harms on young patients.
More articles on quality:
20% of hospitals don’t have a policy to handle ‘never events’
3 thoughts on patient safety from a nurse and quality improvement manager
New trigger tool allows for consistent tracking of adverse events
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.